Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biaxin Could Benefit From Flu Vaccine Shortage Ahead Of Generic Competition

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott cautions that it is too early in the flu season to accurately predict the potential sales impact on the antibiotic brand, which is expected to face generic competition in May 2005. The company’s fourth quarter forecast assumes a conservative impact from the flu vaccine shortage.

You may also be interested in...



Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension

The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.

Biaxin Transition: XL Accounts For 65% Of Franchise Sales

Biaxin XL (extended-release clarithromycin) accounts for approximately 65% of sales of the Biaxin franchise, Abbott said Jan. 18

Biaxin Transition: XL Accounts For 65% Of Franchise Sales

Biaxin XL (extended-release clarithromycin) accounts for approximately 65% of sales of the Biaxin franchise, Abbott said Jan. 18

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel